The Ectodermal Dysplasias-Burden of Disease Score: Development and Validation of an Ectodermal Dysplasia Family/Parental Burden Score.


Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
30 Aug 2023
Historique:
received: 22 10 2022
accepted: 17 05 2023
medline: 31 8 2023
pubmed: 30 8 2023
entrez: 30 8 2023
Statut: epublish

Résumé

Ectodermal dysplasias are genetic conditions affecting the development and/or homeostasis of 2 or more ectodermal derivatives, including hair, teeth, nails, and certain glands. No tool is available to assess the burden of ectodermal dysplasias and its multidimensional impact on patients and their families. This study developed and validated a familial/parental 19-item burden questionnaire designed specifically for ectodermal dysplasias. Each group of questions was linked to 1 of the following dimensions: (i) Impact of the disease on social life and hobbies; (ii) Future prospects; (iii) Restraint of the disease on outdoor activities; (iv) Financial burden of the disease; (v) Acceptance of the disease. Cronbach's alpha was 0.91 for the entire Ectodermal Dysplasias-Burden of Disease (ED-BD) scale, confirming excellent internal coherence. Intradimensional coherences all demonstrated excellent reliability (α > 0.76). The ED-BD questionnaire was highly correlated with the Short Form-12 and Psychological General Well Being Index validated questionnaires. Cultural and linguistic validation in US English was conducted. Development and validation of the questionnaire was based on data from patients with the 2 main ectodermal dysplasias subtypes. This ED-BD questionnaire represents the first specific assessment tool for evaluating the familial/parental burden of ectodermal dysplasias.

Identifiants

pubmed: 37646348
doi: 10.2340/actadv.v103.5203
pmc: PMC10547059
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv5203

Références

J Appl Genet. 2016 Feb;57(1):51-61
pubmed: 26294279
Qual Life Res. 2005 Feb;14(1):71-5
pubmed: 15789942
J R Soc Med. 2001 Nov;94(11):563-6
pubmed: 11691892
Clin Cosmet Investig Dermatol. 2020 Aug 06;13:521-528
pubmed: 32821144
J Clin Exp Neuropsychol. 1994 Feb;16(1):93-104
pubmed: 8150893
Pediatr Dermatol. 2010 May-Jun;27(3):260-5
pubmed: 20609143
Control Clin Trials. 1991 Aug;12(4 Suppl):204S-216S
pubmed: 1663856
Orphanet J Rare Dis. 2020 Jan 10;15(1):7
pubmed: 31924237
Health Qual Life Outcomes. 2013 Jan 07;11:2
pubmed: 23295151
J Investig Dermatol Symp Proc. 2004 Mar;9(2):97-100
pubmed: 15083772
Acta Odontol Scand. 2017 Nov;75(8):564-572
pubmed: 28754083
Value Health. 1999 Mar-Apr;2(2):113-27
pubmed: 16674343
Br J Dermatol. 2015 Dec;173(6):1405-10
pubmed: 26281012
Qual Life Res. 1999;8(1-2):1-8
pubmed: 10457733
Psychol Bull. 1990 Mar;107(2):238-46
pubmed: 2320703
Psychometrika. 1951 Jun;16(2):167-88
pubmed: 14844557
Orphanet J Rare Dis. 2013 Feb 15;8:28
pubmed: 23414570
Br J Dermatol. 2007 Mar;156(3):528-38
pubmed: 17300244
Value Health. 2005 Mar-Apr;8(2):94-104
pubmed: 15804318
Orphanet J Rare Dis. 2018 Sep 18;13(1):162
pubmed: 30227882
Orphanet J Rare Dis. 2019 Nov 26;14(1):271
pubmed: 31771608
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1429-1439
pubmed: 28426906
Genes (Basel). 2022 Dec 10;13(12):
pubmed: 36553593
Med Decis Making. 1999 Apr-Jun;19(2):128-40
pubmed: 10231075
Exp Dermatol. 2019 Oct;28(10):1190-1195
pubmed: 31585491
Qual Life Res. 2001;10(2):105-15
pubmed: 11642680
Qual Life Res. 2018 May;27(5):1171-1179
pubmed: 29260445
Am J Cardiol. 1984 Oct 1;54(7):908-13
pubmed: 6333175

Auteurs

Helene Dufresne (H)

Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Filière Maladies Rares Dermatologiques (FIMARAD), ERN-Skin, Hôpital Universitaire Necker- Enfants Malades, Assistance Publique - Hôpitaux de Paris-Centre (AP-HP5), Paris, France.

Oriane Maincent (O)

Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Filière Maladies Rares Dermatologiques (FIMARAD), ERN-Skin, Hôpital Universitaire Necker- Enfants Malades, Assistance Publique - Hôpitaux de Paris-Centre (AP-HP5), Paris, France.

Charles Taieb (C)

Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Filière Maladies Rares Dermatologiques (FIMARAD), ERN-Skin, Hôpital Universitaire Necker- Enfants Malades, Assistance Publique - Hôpitaux de Paris-Centre (AP-HP5), Paris, France.

Christine Bodemer (C)

Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Filière Maladies Rares Dermatologiques (FIMARAD), ERN-Skin, Hôpital Universitaire Necker- Enfants Malades, Assistance Publique - Hôpitaux de Paris-Centre (AP-HP5), Paris, France.

Smail Hadj-Rabia (S)

Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Filière Maladies Rares Dermatologiques (FIMARAD), ERN-Skin, Hôpital Universitaire Necker- Enfants Malades, Assistance Publique - Hôpitaux de Paris-Centre (AP-HP5), Paris, France. smail.hadj@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH